Ultragenyx Pharmaceutical Inc.
Securities Investigation
Investors who purchased or acquired RARE securities are encouraged to come forward.
Investigation opened September 8, 2026
Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Ultragenyx Pharmaceutical Inc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Ultragenyx Pharmaceutical Inc. (RARE) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE). Investors who purchased Ultragenyx securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Ultragenyx has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
- 1Whether Ultragenyx Pharmaceutical Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- 2Whether Ultragenyx Pharmaceutical Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- 3Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
Key Dates
An investigation is not a lawsuit. If a complaint is filed, a lead plaintiff deadline will be set and posted here.
Why Did RARE Stock Drop?
On September 2, 2026, Ultragenyx issued a press release “announc[ing] results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome.” Per the press release, “[t]he study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI).” On this news, Ultragenyx’s stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026.
How Is Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stock Trading Today?
What Happens After You Contact Us?
Tell us about your purchase
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team reviews your trades at no cost or obligation.
We keep you updated
If a case is filed, we'll contact you about your options and any deadlines.
Submitting information does not create an attorney-client relationship. Our firm works on a contingency fee basis, and you do not need to have sold your shares to contact us.
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Has a lawsuit been filed against Ultragenyx Pharmaceutical Inc.?
No complaint has been filed. BG&G is investigating whether investors may have claims. If a securities class action is filed, this page will be updated with the court, class period, and lead plaintiff deadline.
What does a securities investigation mean?
The firm is reviewing public disclosures, stock price movements, and other information to determine whether a company or its officers may have violated the federal securities laws. An investigation does not mean wrongdoing has been established.
Why should I contact the firm now?
Sharing your information early lets us review your transactions and notify you promptly if a case is filed, including any deadline to seek appointment as lead plaintiff.
Does it cost anything?
No. Our firm works on a contingency fee basis, and there is no cost or obligation to contact us.
I sold my RARE shares. Can I still contact you?
Yes. Potential claims generally depend on when you purchased and whether you suffered a loss, not on whether you still hold the shares.
What documents should I have ready?
Brokerage statements or trade confirmations showing your RARE purchases, sales, and holdings, including dates, share counts, and prices.